B
70.72
-3.21 (-4.34%)
| Penutupan Terdahulu | 73.93 |
| Buka | 73.38 |
| Jumlah Dagangan | 3,652,468 |
| Purata Dagangan (3B) | 2,596,016 |
| Modal Pasaran | 13,551,860,736 |
| Harga / Jualan (P/S) | 28.35 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 24 Feb 2026 |
| Margin Operasi (TTM) | -89.00% |
| EPS Cair (TTM) | -3.56 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -44.80% |
| Nisbah Semasa (MRQ) | 4.57 |
| Aliran Tunai Operasi (OCF TTM) | -500.42 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -261.20 M |
| Pulangan Atas Aset (ROA TTM) | -48.27% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | BridgeBio Pharma, Inc. | Menaik | Menaik |
AISkor Stockmoo
-0.4
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -5.0 |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.40 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.97% |
| % Dimiliki oleh Institusi | 98.14% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 125.00 (Evercore ISI Group, 76.75%) | Beli |
| Median | 95.00 (34.33%) | |
| Rendah | 80.00 (Barclays, 13.12%) | Beli |
| Purata | 95.22 (34.64%) | |
| Jumlah | 9 Beli | |
| Harga Purata @ Panggilan | 71.51 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JP Morgan | 10 Mar 2026 | 94.00 (32.92%) | Beli | 74.32 |
| Evercore ISI Group | 25 Feb 2026 | 125.00 (76.75%) | Beli | 66.54 |
| Morgan Stanley | 25 Feb 2026 | 98.00 (38.57%) | Beli | 66.54 |
| 06 Jan 2026 | 96.00 (35.75%) | Beli | 73.99 | |
| Oppenheimer | 25 Feb 2026 | 81.00 (14.54%) | Beli | 66.54 |
| 13 Feb 2026 | 83.00 (17.36%) | Beli | 75.25 | |
| Truist Securities | 25 Feb 2026 | 95.00 (34.33%) | Beli | 66.54 |
| 08 Jan 2026 | 86.00 (21.61%) | Beli | 73.82 | |
| HC Wainwright & Co. | 17 Feb 2026 | 100.00 (41.40%) | Beli | 75.85 |
| Wells Fargo | 13 Feb 2026 | 98.00 (38.57%) | Beli | 75.25 |
| 20 Jan 2026 | 88.00 (24.43%) | Beli | 77.19 | |
| Barclays | 28 Jan 2026 | 80.00 (13.12%) | Beli | 77.49 |
| Leerink Partners | 15 Dec 2025 | 86.00 (21.61%) | Beli | 74.51 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ELLIS ANDREA | - | 66.54 | -64,921 | -4,319,843 |
| VALANTINE HANNAH | - | 66.48 | -25,484 | -1,694,176 |
| Jumlah Keseluruhan Kuantiti Bersih | -90,405 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -6,014,020 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 66.51 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| ELLIS ANDREA | Pengarah | 04 Mar 2026 | Jual automatik (-) | 64,921 | 66.54 | 4,319,843 |
| ELLIS ANDREA | Pengarah | 04 Mar 2026 | Pelaksanaan pilihan | 64,921 | - | - |
| VALANTINE HANNAH | Pengarah | 27 Feb 2026 | Jual automatik (-) | 25,484 | 66.48 | 1,694,176 |
| VALANTINE HANNAH | Pengarah | 27 Feb 2026 | Pelaksanaan pilihan | 25,484 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |